Local Application of Transcutaneous Carbon Dioxide Paste Decreases Inflammation and Accelerates Wound Healing

Rika Amano-Iga 1, Takumi Hasegawa 1, Daisuke Takeda 1, Aki Murakami 1, Nanaye Tategai 1, Izumi Saito 1, Satomi Arimoto 1, Yasuasa Kakei 1, Akiko Sakakibara 1, Masaya Akashi 1

1. Oral and Maxillofacial Surgery, Kobe University Hospital, Kobe, JPN

Corresponding author: Takumi Hasegawa, hasetaku@med.kobe-u.ac.jp

Abstract

Introduction: Delayed wound healing after surgery lowers the long-term quality of a patient’s life and leads to discomfort and pain. However, treatments for wound healing are often difficult and have not yet been fully established. In this study, we investigated the effect of a special paste that can be administered transcutaneously and holds a non-gaseous carbon dioxide (CO2) source in its carrier, which can be applied to the head and neck region for wound healing in a rat skin defect model.

Methods: Forty-eight Sprague Dawley rats were randomized into control and CO2 groups. We punched a 6.2-mm wound on the back of each rat. The control rats were left untreated, whereas rats in the CO2 group were treated with the CO2 paste every day after surgery. We evaluated wound healing 3, 7, 14, and 21 days after wounding by analyzing the diameter of the wound, gene expression of inflammatory markers vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β, hypoxia-inducible factor (HIF)-1α, interleukin (IL)-1β, and IL-6 using quantitative real-time polymerase chain reaction, hematoxylin and eosin, and immunohistochemical staining patterns.

Results: Rats in the CO2 group showed accelerated wound healing compared to those in the control group. Furthermore, VEGF and TGF-β were overexpressed, whereas HIF-1α, IL-1β, and IL-6 were downregulated in the rats treated with CO2. Immunohistochemical analysis also revealed similar patterns of expression.

Conclusion: Taken together, the CO2 paste promoted wound healing by regulating the hypoxic environment, reducing inflammation, and accelerating angiogenesis.

Categories: Plastic Surgery, Therapeutics, Oral Medicine

Keywords: transcutaneous co2, hypoxia, blood flow, angiogenesis, wound healing

Introduction

The skin functions as a protective physical barrier against a variety of environmental insults and is critical for homeostasis [1]. Wound dressings are used for the temporary treatment of damaged and wounded skin [2]. In oral surgery, the skin protects against possible infection after head and neck surgery and facial injuries. Delayed wound healing after surgery or injury causes discomfort and pain, thereby lowering the long-term quality of life in patients. Thus, rapid wound healing is imperative.

After head and neck surgery and injury, a delay in wound healing is likely to cause infection, prolonged and expensive hospital stay, and further delay in additional treatment [3]. Microwave radiation and lasers have been used to enhance wound healing. However, these treatment strategies are associated with disadvantages, such as negative effects on the heart and high costs [4]. Transcutaneous carbon dioxide (CO2) therapy has been developed for use in humans and animal models to evaluate its efficacy in treating various conditions, for example, medical and beauty treatments [5-7]. This therapeutic strategy is safe and benefits human health by affecting various biological processes. We have previously reported the use of a topical cutaneous CO2 hydrogel to accelerate the repair of a fracture and enhance angiogenesis and blood flow [8]. Transcutaneous CO2 therapy also improves the blood flow and angiogenesis in skin flaps [9] and stimulates muscle injury repair [10].

However, studies done so far have used gaseous CO2 that cannot be applied to the head and neck region. A CO2 paste has been developed that reacts with the moisture on the surface of the skin without letting pure carbon dioxide gas generate carbon dioxide in the applied material and allowing efficient absorption of carbon dioxide from the skin. Thus, this study aims at using CO2 paste to repair skin defects in Sprague Dawley rats and investigating wound healing using gene expression analysis and immunohistochemistry.
Materials And Methods

Animals
Healthy, adult male seven-week-old Sprague Dawley rats were procured from Charles River Laboratories Inc (Tokyo, Japan). Six rats each were randomly divided into two groups: the CO\textsubscript{2}-treated group (CO\textsubscript{2} group: n = 6 rats/time point) and control group (n = 6 rats/time point). All animal experiments were performed according to the Kobe University Animal Experimentation Regulations (approval number P171203). All rats used in the experiment did not receive any other medication. The rats were analyzed 3, 7, 14, and 21 days after wound generation.

Wound generation
Before wounding, the rats were anesthetized using isoflurane (Pfizer Inc., NY, USA) in O\textsubscript{2} and injected intraperitoneally with 45 mg/kg body weight of pentobarbital (Kyoritsu Seiyaku, Tokyo, Japan). The dorsal skin was shaved following which a 6.2-mm wound was punched on the back of each rat.

CO\textsubscript{2} paste treatment
The CO\textsubscript{2} paste (comprising sodium hydrogen carbonate and malic acid that generated CO\textsubscript{2} gas) was obtained from CO\textsubscript{2}TECH (Kobe, Japan). The CO\textsubscript{2} paste contained 1,3-butylene glycol (about 80%), and other components (about 20 %) including sodium hydrogen carbonate, malic acid, sodium dihydrogen phosphate, alkyl-modified carboxyvinyl polymer, and carboxyvinyl polymer. The wound on the rats in the CO\textsubscript{2} group was covered with the CO\textsubscript{2} paste for 10 minutes every day after surgery. The control group rats were wounded and the wounds were left untreated without the CO\textsubscript{2} paste.

Analyzing wound closure
The wounds were photographed 0, 3, 7, 14, and 21 days post-wounding and were measured using ImageJ (a public domain software available at https://imagej.nih.gov/ij/). Wound closure was calculated using the following formula: Wound closure (%) = ([wound area on day 0 - wound area on the indicated day]/wound area on day 0) × 100.

Quantitative real-time polymerase chain reaction (PCR)
We measured the mRNA levels of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1\textalpha\ (HIF-1\textalpha), transforming growth factor-\textbeta\ (TGF-\textbeta), interleukin-1\textbeta\ (IL-1\textbeta), and interleukin-6 (IL-6). The rats were sacrificed 3, 7, 14, and 21 days after injury. Tissue samples were collected from around the wound from which total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA) and treated using the RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA was synthesized (1,000 ng of total RNA) using the High-Capacity cDNA (complementary DNA) Reverse Transcription Kit (Applied Biosystems, Foster City, CA). mRNA levels were quantified using the Step One Real-Time PCR System (Applied Biosystems, Foster City, CA). Real-time PCR (20 µl) was performed using 0.5 \mu M forward primer, 0.5 \mu M reverse primer, 1 µl of template cDNA, and 10 µl (2+) Power SYBR Green Master Mix (Applied Biosystems, Foster City, CA). The PCR conditions were as follows: 95°C for 10 min followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. Target gene expression was normalized to \beta-actin and fold-change was calculated using the 2-\Delta\Delta CT method (Applied Biosystems, Foster City, CA). \beta-actin, VEGF, HIF-1\textalpha, and IL-6 primers were obtained from Invitrogen and those for TGF-\textbeta\ and IL-1\textbeta were procured from Qiagen. The primer information is presented in Tables 1-2.

| Gene name | Primer sequence (5'-3') |
|-----------|------------------------|
| \beta-actin | Fw: GAT GAG ATT GGC ATG GCT TT Rv: CAC CTT CAC CGT TCC AGT TT |
| VEGF | Fw: GTA TAT CTT CAA GGC GTC CTG TGT G Rv: GAT CCG CAT GAT CTG CAT AGT GAC |
| HIF-1\textalpha | Fw: CCT GCA CTG AAC ATG GAC GGT GC Rv: CCA TCA GAA GGA CTT GCT GGC T |
| IL-6 | Fw: GGT CTT CTG GAG TTC CGT TTT T Rv: GGT CTT GGT CCT TAG CCA CTC |

**TABLE 1: Specific primer sequence for real-time polymerase chain reaction analysis**

VEGF = Vascular endothelial growth factor; HIF-1\textalpha = Hypoxia-inducible factor 1\textalpha; IL-6 = Interleukin-6; Fw = Forward primer; Rv = Reverse primer; A = Adenine; G = Guanine; C = Cytosine; T = Thymine

2021 Amano-Iga et al. Cureus 13(11): e19518. DOI 10.7759/cureus.19518
| Gene name | Primer                        |
|-----------|-------------------------------|
| TGF-β     | Rn_Tgfb1_1_SG QuantiTect Primer Assay cat no: QT00187796 |
| IL-1β     | Rn_Il1b_1_SG QuantiTect Primer Assay cat no: QT00181657 |

### TABLE 2: Primers used for real-time polymerase chain reaction analysis

TGF-β = transforming growth factor β; IL-1β = Interleukin-1β

---

**Hematoxylin and eosin (H&E) staining**

The tissues were fixed in 4% paraformaldehyde and embedded in paraffin wax. The paraffin-embedded 6-µm thick samples were sectioned using a microtome and stained with H&E. We defined wound healing as a condition indistinguishable from tissues adjacent to the site of the wound. Images of the sections were captured using BZ-X700 (Keyence, Osaka, Japan) at a magnification of ×200.

**Immunohistochemistry**

Immunohistochemistry was performed using the tissue sections from the wound to detect the protein levels of VEGF, HIF-1α, and TGF-β (10 each). The formalin-fixed and paraffin-embedded skin tissues were pretreated with proteinase K (Dako company, CA, USA), quenched with 0.05% H₂O₂, and incubated overnight at 4°C with the following primary antibodies in Can Get Signal Immunostain Solution A (Toyobo, Osaka, Japan): mouse anti-VEGFA antibody (1:200, Abcam, Cambridge, UK) and anti-HIF-1α antibody (1:100, Abcam). The rabbit anti-TGFB1 antibody (1:100, Abcam) was heat-treated with ethylenediaminetetraacetic acid (EDTA) instead of proteinase K. Following washes using phosphate-buffered saline, we incubated the sections with peroxidase-conjugated labeled anti-mouse (cat no. 424131) or anti-rabbit (cat no. 424141) antibodies (Histofine Simplestain MAX-PO; Nichirei, Tokyo, Japan) for 30 min. Following staining with diaminobenzidine and counterstaining with hematoxylin, the tissue sections were visualized and photographed using the BZ-X700 fluorescence microscope (Keyence, Osaka, Japan) at a magnification of ×400. The positively stained areas were quantified using the Hybrid cell count BZ-H3C software (Keyence, Osaka, Japan).

**Statistical analysis**

Data collection and statistical analyses were performed using Excel-Toukei 2012 (Social Survey Research Information Co. Ltd., Tokyo, Japan). Data have been represented as mean ± standard error. Data from the two groups were analyzed using the Mann-Whitney U-test. A value of p < 0.05 was considered statistically significant.

**Results**

**Rate of wound healing**

Figure 1 shows the representative photographs of the wound on days 0, 3, 7, 14, and 21.

---

**FIGURE 1:** Representative photographs of the wound on days 0, 3, 7, 14, and 21.
Figure 2 shows the percentage of wound healing in the control and CO\textsubscript{2} groups. Three days after the wounds were punched, the rates of wound healing in the control and CO\textsubscript{2} groups were 21.04\% ± 3.62\% and 32.98\% ± 4.48\%, respectively. On day 7, the rates of wound healing in the control and CO\textsubscript{2} groups were 38.02\% ± 3.66\% and 65.11\% ± 2.33\%, respectively (p < 0.05). On day 14, the rates of wound healing in the control and CO\textsubscript{2} were 78.24\% ± 1.75\% and 86.57\% ± 0.90\%, respectively (p < 0.05). On day 21, the rates of wound healing in the control and CO\textsubscript{2} groups were 82.74\% ± 1.75\% and 93.50\% ± 0.68\%, respectively (p < 0.05). Thus, the rates of wound healing were significantly higher after three days in rats treated with the CO\textsubscript{2} paste as compared to those in the control rats.

Gene expression profiles

VEGF levels peaked seven days after injury (Figure 3). Real-time PCR showed that VEGF expression was significantly higher in the CO\textsubscript{2} group as compared to that in the control group after seven days (p < 0.05).
The expression of TGF-β (days 3, 7, and 14) was significantly higher in the CO₂ group than that in the control group (p < 0.05; Figure 4). Furthermore, the expression of HIF-1α (days 3 and 7; Figure 5), IL-1β (days 7 and 14; Figure 6), and IL-6 (days 3, 7, and 14; Figure 7) was significantly lower in the CO₂ group than that in the control group (p < 0.05).

**FIGURE 4: The mRNA expression of TGF-β.**
The mRNA expression was evaluated using quantitative real-time polymerase chain reaction (PCR)

Vertical bars indicate standard deviation

TGF-β = transforming growth factor-β; * = p < 0.05.

**FIGURE 5: The mRNA expression of HIF-1α.**
The mRNA expression was evaluated using quantitative real-time polymerase chain reaction (PCR)

HIF-1α = Hypoxia-inducible factor-1α; * = p < 0.05.
**FIGURE 6: The mRNA expression of IL-1β.**
The mRNA expression was evaluated using quantitative real-time polymerase chain reaction (PCR).

IL-1β = Interleukin-1β; * = p < 0.05.

**FIGURE 7: The mRNA expression of IL-6.**
The mRNA expression was evaluated using quantitative real-time polymerase chain reaction (PCR).

IL-6 = Interleukin-6; * = p < 0.05.

**H&E staining**
Figure 8 shows the H&E stained sections of wounds in the two groups on different days. On day 3, the site of the wound comprised inflammatory cells in both groups. On day 7, wounds in the control rats contained a small population of fibroblasts. However, rats from the CO₂ group showed a higher abundance of proliferating fibroblasts. Moreover, fibroblasts were uniformly and densely arranged in the CO₂ group as compared to the control group. On day 14, the fibroblast content gradually decreased in both groups. The rats from the control group showed remains of a scar. However, rats in the CO₂ group showed better healing around the wound. Rats from the CO₂ group showed uniformly arranged collagen fibers after 21 days. These rats only had a scar near the epithelium. In contrast, rats from the control group possessed a lower abundance of collagen fibers and a full scar.
FIGURE 8: H&E histological observation of wounds in both groups on 3, 7, 14, and 21 days post-wounding
Histological observation of wounds at ×40 (upper left corner, scale bar = 1000) and ×200 (scale bar = 100)

Immunohistochemical analysis
HIF-1α, VEGF, and TGF-β protein levels in the wounds were assessed using immunohistochemistry. HIF-1α-positive cells were more abundant in the control group across all the time points (Figures 9, 10).

FIGURE 9: HIF-1α immunohistochemistry of wound sections of both groups on 3, 7, 14, and 21 days post-wounding
HIF-1α = Hypoxia-inducible factor-1α

Scale bar = 100 and magnification ×400
The CO₂ group showed higher VEGF expression as compared to that in the control group on days 7, 14, and 21 (Figures 11, 12).

**FIGURE 10: HIF-1α quantitative immunohistochemical analysis of the primary antibody-positive area ratio**

HIF-1α = Hypoxia-inducible factor-1α; * = p < 0.05

**FIGURE 11: VEGF immunohistochemistry of wound sections of both groups on 3, 7, 14, and 21 days post-wounding**

VEGF = Vascular endothelial growth factor

Scale bar = 100 μm; and magnification ×400
Moreover, the CO\(_2\) group showed higher levels of TGF-\(\beta\) as compared to that in the control group across all time points (Figures 13, 14). The data from immunohistochemistry were comparable to that obtained from real-time PCR.

![Figure 12: VEGF quantitative immunohistochemical analysis of the primary antibody-positive area ratio](image)

**FIGURE 12: VEGF quantitative immunohistochemical analysis of the primary antibody-positive area ratio**

VEGF = Vascular endothelial growth factor; * = p < 0.05

Moreover, the CO\(_2\) group showed higher levels of TGF-\(\beta\) as compared to that in the control group across all time points (Figures 13, 14). The data from immunohistochemistry were comparable to that obtained from real-time PCR.

![Figure 13: TGF-\(\beta\) immunohistochemistry of wound sections of both groups on 3, 7, 14, and 21 days post-wounding](image)

**FIGURE 13: TGF-\(\beta\) immunohistochemistry of wound sections of both groups on 3, 7, 14, and 21 days post-wounding**

TGF-\(\beta\) = transforming growth factor-\(\beta\)

Scale bar = 100\(\mu\)m and magnification \(\times 400\)
FIGURE 14: TGF-β quantitative immunohistochemical analysis of the primary antibody-positive area ratio

TGF-β = transforming growth factor-β; * = p < 0.05

Discussion

In this study, we have demonstrated that CO₂ paste accelerated wound healing by upregulating VEGF and TGF-β and downregulating HIF-1α, IL-1β, and IL-6 in wounded rats.

CO₂ therapy mechanistically involves the percutaneous absorption of CO₂ that enhances vasodilation, blood flow, Bohr effect, and tissue O₂ partial pressure. We have previously demonstrated that transcutaneous administration of CO₂ results in an artificial Bohr effect by increasing tissue O₂ pressure upon CO₂ absorption [11]. Transcutaneous CO₂ therapy has been used in humans and animal models to study its medical and cosmetic effects [12,13]. We have previously demonstrated that our transcutaneous CO₂ system improves blood flow and increases angiogenesis [8,9]. Gaseous CO₂ cannot be used in the head and neck region. In this study, we used a CO₂ paste for wound healing that may be applied to the head and neck.

Wound healing is a complex process that involves multiple biological processes, such as inflammation, formation of granulation tissue, re-epithelialization, and matrix formation and remodeling [14]. Wound healing can be divided into three phases: inflammation, proliferation, and maturation [1]. Numerous cells, growth factors, and cytokines play an important role in wound healing. Thus, we investigated the roles of VEGF, TGF-β, HIF-1α, IL-1β, and IL-6.

HIF-1α is a protein that senses changes in environmental O₂ and is involved in transcriptional regulation during hypoxia [15]. Hypoxia is an important prognostic determinant of wound repair and limits dermal wound healing [16]. Early-stage hypoxia induces wound healing, while prolonged hypoxia delays wound healing [17]. In this study, HIF-1α was upregulated in the control rats exposed to hypoxic stress. However, rats in the CO₂ group failed to exhibit sustained hypoxia.

VEGF is produced by endothelial cells, fibroblasts, and macrophages and is important in wound healing. VEGF promotes the early events in angiogenesis, particularly endothelial cell migration and proliferation [14]. VEGF levels gradually increase between the early and middle stages of wound healing [2]. We have previously reported the CO₂ therapy-induced increase in the expression of VEGF in rat fracture, skin flap, and muscle models [8,9,18]. In this study, VEGF levels significantly increased in the CO₂ group on day 7. This indicates that the CO₂ paste stimulates the expression of growth factors. Under hypoxia, VEGF is primarily regulated by HIF-1α [19]. VEGF is secreted at higher concentrations of O₂ [20]. We observed a decrease in hypoxia and upregulation of VEGF. Thus, it may stimulate angiogenesis and wound healing.

TGF-β is important for angiogenesis and wound healing [1]. TGF-β is a multifunctional growth factor that exerts pleiotropic effects on wound healing by regulating cell proliferation, migration, differentiation, extracellular matrix production, and immune modulation [21]. TGF-β is produced by macrophages, fibroblasts, keratinocytes, platelets, and endothelial cells [14,22] and is important in inflammation, angiogenesis, re-epithelialization, fibroblast proliferation, collagen synthesis and deposition, and connective tissue regeneration [1,14,23]. Moreover, this growth factor functions in wound healing by facilitating fibroblast recruitment to the collagen matrix [24]. In this study, there was a significant increase in the mRNA levels of TGF-β in the rats of the CO₂ group on days 3, 7, and 14.
Scarless wounds are characterized by a lack of inflammation, regeneration of dermal appendages, and orderly deposition of collagen [25]. Fibroblasts are cells that synthesize collagen and extracellular matrix that play a critical role in wound healing [26]. Gopal et al. reported enhanced wound healing in an open excision rat model and an increase in VEGF and TGF-β expression [26]. TGF-β is overexpressed in keloid tissues [27]. A gradual decrease in the expression of TGF-β indicates the suppression of excessive scar formation. Histopathologically, fibroblasts were arranged in a uniform and dense manner in the rats of the CO₂ group on day 7. On day 14, the skin around the wound was replaced with collagen fibers that enabled wound shrinkage. The peak in the expression of TGF-β on day 7 in the CO₂ group highlighted accelerated wound healing, implicating the CO₂ paste in inducing normal healing. We observed a slight difference between our real-time PCR and immunostaining data for TGF-β. TGF-β mRNA levels peaked on day 3, while its protein levels peaked on day 7. This could be attributed to delayed protein synthesis.

An increase in inflammatory cytokines, such as IL-1β, prolongs inflammation and delays healing [28]. Hypoxia induces inflammation [29]. The levels of inflammatory cytokines (IL-6) and C-reactive protein increase under hypoxic stress [30]. Yu et al. showed the downregulation of IL-1β and upregulation of VEGF in a rat skin defect model with microcurrent dressing [2]. In this study, the expression of IL-6 (days 3, 7, and 14) and IL-1β (days 7 and 14) were lower in the rats of the CO₂ group than that in the control rats. Therefore, CO₂ paste might accelerate wound healing by regulating inflammatory cytokines and hypoxia.

However, this study has some limitations. First, this study involves an animal model and has not been conducted in humans. This is important since rat and human skin are different. Second, this study does not address the optimum conditions of CO₂ treatment, such as application time and the number of days of treatment. Finally, the rats of the control group received only wound generation without any control paste. Therefore, the influences of treatment without a CO₂ paste were not completely excluded. These limitations should be investigated in further studies.

Conclusions
In summary, this study demonstrated that CO₂ paste accelerated wound healing by upregulating VEGF and TGF-β and downregulating HIF-1α, IL-1β, and IL-6 in a rat model of skin defect. The application of CO₂ paste accelerated normal wound healing by improving hypoxia and angiogenesis and reducing the expression of inflammatory cytokines. Further experiments, including human clinical studies, are needed to investigate the efficacy of CO₂ paste on skin wounds. This will enable the development of novel strategies for patients with skin defects in the future.

Additional Information
Disclosures
Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Animal subjects: Kobe University Animal Experimentation Regulations Issued protocol number P171203. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors declare that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Baum CL, Arpey CJ: Normal cutaneous wound healing: clinical correlation with cellular and molecular events. Dermatol Surg. 2005, 31:674-86; discussion 866. 10.1111/j.1524-4725.2005.31642
2. Yu C, Xu ZX, Hao YH, et al.: A novel microporous dressing for wound healing in a rat skin defect model. Mil Med Res. 2019, 6:22. 10.1186/s40779-019-0213-x
3. Penel N, Lefebvre D, Fournier C, Sarini J, Kara A, Lefebvre JL: Risk factors for wound infection in head and neck cancer surgery: a prospective study. Head Neck. 2001, 23:447-55. 10.1002/hed.1058
4. Dorsett-Martin WA: Rat models of skin wound healing: a review. Wound Repair Regen. 2004, 12:591-9. 10.1111/j.1067-1927.2004.12601.x
5. Yamamoto N, Hashimoto M: Immersion in CO₂-rich water containing NaCl diminishes blood pressure fluctuation in anesthetized rats. Int J Biometeorol. 2007, 52:109-16. 10.1007/s00484-007-0102-y
6. Brandi C, Grimaldi L, Nisi G, et al.: The role of carbon dioxide therapy in the treatment of chronic wounds. In Vivo. 2010, 24:223-6.
7. Brandi C, D’Aniello C, Grimaldi L, Bosi B, Dei I, Lattarulo P, Alessandrini C: Carbon dioxide therapy in the treatment of localized adiposities: clinical study and histopathological correlations. Aesthetic Plast Surg. 2001, 25:170-4. 10.1007/s00266010116
8. Koga T, Niiura T, Lee SY, et al.: Topical cutaneous CO₂ application by means of a novel hydrogel accelerates fracture repair in rats. J Bone Joint Surg Am. 2014, 96:2077-84. 10.2106/JBJS.M.01498
9. Saito I, Hasegawa T, Ueba T, et al.: Effect of local application of transcutaneous carbon dioxide on survival of random-pattern skin flaps. J Plast Reconstr Aesthet Surg. 2018, 71:1644-51. 10.1016/j.bjps.2018.06.010
10. Akahane S, Sakai Y, Ueba T, Nishimoto H, Inoue M, Niikura T, Kuroda R: Transcutaneous carbon dioxide application accelerates muscle injury repair in rat models. Int Orthop. 2017, 41:1007-15. 10.1007/s00264-017-3417-2

11. Sakai Y, Miwa M, Oe K, et al.: A novel system for transcutaneous application of carbon dioxide causing an "artificial Bohr effect" in the human body. PloS One. 2011, 6:e24137. 10.1371/journal.pone.0024137

12. Schmidt J, Monnet P, Normand B, Fahy R: Microcirculatory and clinical effects of serial percutaneous application of carbon dioxide in primary and secondary Raynaud’s phenomenon. Vasa. 2005, 34:95-100. 10.1024/0301-1526.34.2.93

13. Brandi C, D’Arienlo C, Grimaldi L, Caiazzo E, Stanghellini E: Carbon dioxide therapy: effects on skin irregularity and its use as a complement to liposuction. Aesthetic Plast Surg. 2004, 28:222-5. 10.1007/s00266-004-2068-z

14. Barrientos S, Stoijadinovic O, Golinko MS, Brem H, Tomic-Canic M: Growth factors and cytokines in wound healing. Wound Repair Regen. 2008, 16:585-601. 10.1111/j.1524-475X.2008.00410.x

15. Biddlestone J, Bandarra D, Rocha S: The role of hypoxia in inflammatory disease (review). Int J Mol Med. 2015, 35:859-69. 10.3892/ijmm.2015.2079

16. Bream RB, Wallace WA, Roy S, et al.: Dermal excisional wound healing in pigs following treatment with topically applied pure oxygen. Mutat Res. 2005, 579:172-81. 10.1016/j.mrfmmm.2005.02.023

17. Hong WX, Hu MS, Esquivel M, et al.: The role of hypoxia-inducible factor in wound healing. Adv Wound Care (New Rochelle). 2014, 3:390-9. 10.1089/wound.2013.0520

18. Oe K, Ueba T, Sakai Y, et al.: The effect of transcutaneous application of carbon dioxide (CO₂) on skeletal muscle. Biochem Biophys Res Commun. 2011, 407:148-52. 10.1016/j.bbrc.2011.02.128

19. Arany Z, Foo SY, Ma Y, et al.: HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α. Nature. 2008, 451:1008-12. 10.1038/nature06613

20. Kimmel HM, Grant A, Ditata J: The presence of oxygen in wound healing. Wounds. 2016, 28:264-70.

21. Kiritsi D, Nyström A: The role of TGFβ in wound healing pathologies. Mech Ageing Dev. 2018, 172:51-8. 10.1016/j.mad.2017.11.004

22. Liarte S, Bernabé-García Á, Nicolás FJ: TGF-β in skin chronic wounds: a keratinocyte perspective. Cells. 2020, 9:10.3390/cells9020306

23. Nall AV, Brownlee RE, Calvin GP, et al.: Transforming growth factor β1 improves wound healing and random flap survival in normal and irradiated rats. Arch Otolaryngol Head Neck Surg. 1996, 122:171-7. 10.1001/archotol.1996.01890140057011

24. Meckmongkol TT, Harmon R, McKeown-Longo P, Van De Water L: The fibronectin synergy site modulates TGF-β-dependent fibroblast contraction. Biochem Biophys Res Commun. 2007, 357:709-14. 10.1016/j.bbrc.2007.06.121

25. Emtzschig HK, Carmeliet P: Hypoxia and inflammation. N Engl J Med. 2011, 364:656-65. 10.1056/NEJMra0910283

26. Hartmann G, Tschöp M, Fischer R, et al.: High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine. 2000, 12:246-52. 10.1006/cyto.1999.0533